Hot Pursuit     18-Apr-24
Piramal Pharma rises after USA facility clears USFDA inspection
Piramal Pharma gained 2.09% to Rs 144.30 after the US drug regulator issued an Establishment Inspection Report (EIR) for the Riverview, USA facility stating the inspection to be closed.
Earlier in February 2024, the US Food and Drug Administration (USFDA) conducted a pre-approval inspection (PAI) inspection of the company’s Riverview (USA) facility from 29th January 2024 to 6th February 2024.

On conclusion of the inspection, a Form-483 was issued with 3 observations. The observations were classified under VAI (Voluntary Action Indicated).

Piramal Pharma is a pharmaceutical company that manufactures and develops a wide range of pharmaceutical solutions to reduce diseases. Piramal Pharma serves customers worldwide.

The pharmaceutical company reported a consolidated net profit of Rs 10.11 crore in Q3 FY24 as compared with net loss of Rs 90.18 crore recorded in Q3 FY23. Revenue from operations rose by 14.1% year-on-year to Rs 1,958.57 crore in Q3 FY24.

Previous News
  Piramal Pharma soars after Bethlehem facility gets USFDA clearance
 ( Hot Pursuit - 09-Nov-23   12:14 )
  Piramal Pharma's Bethlehem unit clears USFDA inspection
 ( Corporate News - 09-Nov-23   14:05 )
  Everest Industries Ltd leads losers in 'B' group
 ( Hot Pursuit - 10-Nov-22   14:46 )
  Piramal Pharma to announce Quarterly Result
 ( Corporate News - 02-Nov-22   19:46 )
  Piramal Pharma reports consolidated net profit of Rs 5.02 crore in the September 2023 quarter
 ( Results - Announcements 28-Oct-23   07:38 )
  Volumes spurt at Piramal Pharma Ltd counter
 ( Hot Pursuit - 05-Mar-24   11:00 )
  Piramal Pharma fixes record date for rights issue
 ( Market Beat - Reports 29-Jul-23   13:09 )
  Piramal Pharma's Lexington facility undergoes USFDA PAI and GMP inspection
 ( Corporate News - 11-Jan-23   11:39 )
  Piramal Pharma reports turnaround Q2 numbers
 ( Hot Pursuit - 28-Oct-23   15:36 )
  Piramal Pharma slips as US FDA issues Form 483 with six observations
 ( Hot Pursuit - 11-Jan-23   13:09 )
  Piramal Pharma gains as Q4 PAT doubles to Rs 101 crore
 ( Hot Pursuit - 13-May-24   16:37 )
Other Stories
  Shree Cement Q1 PAT drops 45% YoY to Rs 318 cr
  06-Aug-24   16:59
  Graphite India gains on reporting turnaround Q1 results
  06-Aug-24   16:41
  Vedanta Q1 PAT jumps 54% YoY to Rs 5,095 cr
  06-Aug-24   16:11
  PFC Q1 PAT jumps 20% YoY to Rs 7,182 cr
  06-Aug-24   15:51
  Symphony hits 52-week high after Q1 PAT soars YoY Rs 88 cr; Board OKs buyback upto Rs 71.40 cr
  06-Aug-24   15:09
  Shivalik Bimetal Controls Ltd leads losers in 'A' group
  06-Aug-24   15:00
  TVS Motor Q1 PAT climbs 23% YoY to Rs 577 crore
  06-Aug-24   14:46
  Indian Terrain Fashions Ltd leads losers in 'B' group
  06-Aug-24   14:45
  Volumes soar at K P R Mill Ltd counter
  06-Aug-24   14:30
  Triveni Turbine spurts as Q1 PAT climbs 32% YoY to Rs 80 cr
  06-Aug-24   14:06
Back Top